In our non-small cell lung cancer cohort, PFS, objective response rate and disease control rate had obvious superiority in the patients with PBRM1 mutation than those without PBRM1 mutation (PFS: HR = .268, 95% CI: 084-.854, p = .04, ORR: 55.56% vs. 20.00%, p = .027, DCR: 100% vs. 75.20%)...the above were fully illustrated the links between the PBRM1 mutation and ICIs response in pan-cancer patients with treated ICIs. PBRM1 mutation be used to a promising immunotherapeutic signature that could guide clinical management and personalized immunotherapy.

In this study, we aimed to identify gene mutations associated with immunotherapy resistance and further informed mechanisms in NSCLC....Survival analysis showed that the overall survival (OS) and PFS of patients with PBRM1 mutations (MT) were significantly shorter than the wild type (WT).

To assess the impact of PBAF complex mutations in non-RCC cohorts treated with ICB profiled with MSK-IMPACT, we restricted our analysis to 11 tumor types with at least 50 patients and at least 5 patients with PBRM1 or ARID2 mutations (n = 2936)...When univariately examining LOF mutations in PBRM1 and ARID2 as well as LOF in PBRM1 alone, they remained significantly associated with adverse OS in non-small-cell lung cancer...In individual cancer types, PBRM1 was correlated with worse OS in non-small-cell lung cancers...